HYBRID EVENT: You can participate in person at Orlando, Florida, USA or Virtually from your home or work.

6th Edition of Global Conference on

Addiction Medicine, Behavioral Health and Psychiatry

October 20-22, 2025 | Orlando, Florida, USA

Clozapine

Clozapine

An antipsychotic drug called clozapine works by assisting in the re-establishment of the proper balance of specific naturally occurring compounds (neurotransmitters) in the brain. It is primarily used to treat mental illnesses like schizophrenia and schizophrenic tendencies that did not respond well to other antipsychotic medications and in which the patient was unable to tolerate other medications because of the extrapyramidal effects of other antipsychotic drugs. This medication has a bioavailability of between 60 and 70 per cent and is processed by the liver and numerous CYP isozymes. The half-life of elimination is 4 to 26 hours. People with schizophrenia who have not responded well to previous antipsychotics or who have been unable to tolerate other medications because of extrapyramidal side effects typically use clozapine. In Parkinson's disease, it is also applied to the treatment of psychosis.  Its usage is advised by several worldwide treatment recommendations and is backed by systematic reviews and meta-analyses. It is recognised as the gold-standard therapy when other medications have not been adequately successful.  Although all current recommendations limit the use of clozapine to patients who have failed two previous antipsychotic medications, there is evidence that clozapine may be utilized as a second-line medication.   Treatment with clozapine has been shown to yield better results in a number of areas, such as a decreased risk of hospitalisation, and a decreased chance of medication cessation.

Committee Members
Speaker at Addiction Medicine, Behavioral Health and Psychiatry 2025 - Nile Stanley

Nile Stanley

University of North Florida, United States
Speaker at Addiction Medicine, Behavioral Health and Psychiatry 2025 - Ann Marie Leonard Zabel

Ann Marie Leonard Zabel

Curry College, United States
Speaker at Addiction Medicine, Behavioral Health and Psychiatry 2025 - Denis Larrivee

Denis Larrivee

University of Navarra, Spain
GAB 2025 Speakers
Speaker at Addiction Medicine, Behavioral Health and Psychiatry 2025 - Scharbach Hugues

Scharbach Hugues

Paris University, France
Speaker at Addiction Medicine, Behavioral Health and Psychiatry 2025 - Alphonsus Obayuwana

Alphonsus Obayuwana

Triple-H Project LLC, United States
Speaker at Addiction Medicine, Behavioral Health and Psychiatry 2025 - Michelle Charbonnier

Michelle Charbonnier

MoNetwork, United States
Speaker at Addiction Medicine, Behavioral Health and Psychiatry 2025 - Monica Zuniga Fajuri

Monica Zuniga Fajuri

Tiburcio Vasquez Health Center, United States

Submit your abstract Today

Watsapp